Australia
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
3429
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
2025-06-30 20:30
2207
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...
2025-06-25 18:05
2403
Academic friend or foe? Yugo research reveals how students supercharge their studies with AI
Despite academic advantages, substantial fears remain about AI's impact
LONDON, June 19, 2025 /PRNewswire/ -- As universities grapple with how to
effectively police AI, new Yugo research reveals the extent to which students
are using it as a powerful study companion.
2025-06-19 05:33
2621
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...
2025-06-18 20:00
2978
Polus holds €425 million initial close for third CLO equity fund
One of Europe's largest raises of its kind highlights Polus' leadership in the CLO and leveraged credit markets. LONDON, June 17, 2025 /PRNewswire/ -- Polus Capital Management ("Polus"), an investment management firm specialising in alternative credit strategies, is pleased to announce the initi...
2025-06-17 22:18
2364
Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64Cu-SAR-bisPSMA. * SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 sta...
2025-06-17 21:04
4270
Ace Green Recycling and Enecell Announce Strategic Agreement to Advance Sustainable Battery Recycling in Australia
Ace to become Enecell's exclusive offtake partner for its lead battery
recycling facility inPerth
Commercial agreement is Ace's first in Australia, the world's largest lithium
producer
HOUSTON, June 16, 2025 /PRNewswire/ -- Ace Green Recycling
2025-06-16 20:00
2380
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...
2025-06-16 19:00
2001
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...
2025-06-16 19:00
2866
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including pr...
2025-06-13 21:01
3916
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T...
2025-06-13 19:35
3094
Dazu Rock Carvings: The Last Monument of World Grotto Art
CHONGQING, China, June 12, 2025 /PRNewswire/ -- Located in southwest China's Chongqing Municipality, the Dazu Rock Carvings have held UNESCO World Heritage status since 1999. Sprawled across 75 recognized cultural relics protection zones, the site shelters over 50,000 breathtaking statues. As one...
2025-06-12 23:29
2862
Cam Model Earned Over $3.4 Million Streaming on LiveJasmin -- 3rd Edition of International Cam Model Day Celebrates a New Era of Creator Careers
LiveJasmin marks model appreciation week and 25 years in the industry with new
opportunities to empower models onwww.cammodelday.com
2025-06-12 01:09
2437
Uzbekistan Sees Foreign Investment Growth of over 60 per cent in 2024
'New Uzbekistan: The Big Country With Big Opportunities – Reform In Action' FDI Report unveiled as Tashkent International Investment Forum Gets Underway TASHKENT, Uzbekistan, June 10, 2025 /PRNewswire/ -- Foreign investment in Uzbekistan is growing rapidly as the country saw an over 60 per cent ...
2025-06-10 17:00
2871
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
HIGHLIGHTS * Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs). * DISCO compared the diagnostic performance of 64C...
2025-06-05 21:01
3322
Mérieux NutriSciences and AsureQuality Announce the Official Launch of Mérieux NutriSciences AQ (MNAQ) Joint Venture
CHICAGO and AUCKLAND, New Zealand, June 2, 2025 /PRNewswire/ -- Mérieux NutriSciences, a global leader in food safety, quality, and sustainability, and AsureQuality,New Zealand's premier food assurance provider, are pleased to announce the official launch of their joint venture,Mérieux NutriScien...
2025-06-02 05:00
3383
NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[ 1] SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Austr...
2025-05-30 00:01
2945
First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has imaged the...
2025-05-29 21:04
2459
Platinum Jets Officially Launches Services and Real-Time Instant Quote Tool for Private Jet Travel
SWANAGE, England, May 27, 2025 /PRNewswire/ -- Platinum Jets, a boutique
private jet charter broker serving a global clientele of business leaders and
luxury travelers, is proud to announce the official launch of its services
along with the debut of its cutting-edgeInstant Quote feature on
2025-05-27 21:00
2155
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7189
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7087
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6428
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6353
